Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has reported robust financial results for the first quarter of the fiscal year 2026 (Q1FY26), demonstrating solid growth across its key markets and business segments.

Financial Highlights

• Gross sales reached ₹137,861.00 million, marking a 10.1% year-over-year growth
• Adjusted net profit increased by 5.7% to ₹29,961.00 million
• EBITDA rose by 19.2% to ₹43,017.00 million, with an EBITDA margin of 31.1%
• Profit before exceptional items and tax grew by 16.6% to ₹39,908.00 million

Market Performance

Sun Pharma continued to strengthen its position in various markets:

India Formulations

• Sales grew by 13.9% to ₹47,211.00 million, accounting for 34.2% of total consolidated sales
• Maintained No. 1 ranking with an increased market share of 8.3% in the Indian pharmaceutical market

US Formulations

• Sales reached US$473.00 million, up 1.4% and contributing 29.3% to total consolidated sales

Global Innovative Medicines

• This segment, formerly known as Specialty business, saw a significant growth of 16.9%, reaching US$311.00 million
• Accounted for 19.3% of Q1FY26 sales

Emerging Markets

• Formulation sales grew by 5.1% to US$298.00 million, representing 18.5% of total consolidated sales

Rest of World

• Formulation sales increased by 15.5% to US$219.00 million, contributing 13.6% to total consolidated sales

R&D and Product Pipeline

Sun Pharma continued its focus on research and development:

• R&D investments for Q1FY26 stood at ₹9,029.00 million, or 6.5% of sales
• The company's innovative R&D pipeline includes six novel entities in clinical stage
• In the US market:
  • 542 approved ANDAs and 119 pending approval
  • 57 approved NDAs and 13 awaiting approval
• During Q1, the company filed 2 ANDAs and received 1 ANDA approval

Management Commentary

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, commented on the results:

"Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business."

Future Outlook

While specific future projections were not provided, the company's strong performance across various markets and its continued investment in R&D suggest a positive outlook. The growth in the Global Innovative Medicines segment and the recent launch of LEQSELVI in the US market are expected to be key drivers for future growth.

Sun Pharma's robust Q1FY26 results demonstrate the company's resilience and ability to grow across diverse markets. With its strong market position in India, expanding presence in the US and emerging markets, and focus on innovative medicines, Sun Pharma appears well-positioned for continued growth in the pharmaceutical industry.

Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has reported robust financial results for the first quarter of fiscal year 2026, demonstrating steady progress across all markets. The company also reaffirmed its strong presence in the United States while clarifying its stance on manufacturing expansion in the region.

Q1 FY26 Financial Highlights

Sun Pharma's consolidated gross sales for Q1 FY26 reached ₹137,861.00 million, marking a significant 10.1% year-over-year growth. The company's adjusted net profit rose by 5.7% to ₹29,961.00 million, excluding exceptional items. However, the reported net profit stood at ₹22,786.00 million, compared to ₹28,356.00 million in Q1 FY25.

Key performance indicators include:

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a substantial increase of 19.2%, reaching ₹43,017.00 million, with an EBITDA margin of 31.1%.

Market Position and R&D Investments

Sun Pharma maintained its leadership position in the Indian pharmaceutical market, increasing its market share from 8.0% to 8.3%. The company launched five new products in the Indian market during Q1 FY26.

Research and Development (R&D) investments remained a priority, with ₹9,029.00 million allocated to R&D activities, representing 6.5% of sales. This commitment to innovation is reflected in Sun Pharma's comprehensive product portfolio, which includes 542 approved ANDAs and 57 approved NDAs in the U.S. market.

U.S. Market Strategy

Addressing the company's stance on its U.S. operations, a Sun Pharma co-executive stated that while the company maintains a strong presence in the United States, there are no immediate plans to expand its manufacturing operations there. The executive emphasized Sun Pharma's established position in the U.S. market, which accounted for 29.3% of total consolidated sales in Q1 FY26.

Management Commentary

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, commented on the results: "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance."

Shanghvi also highlighted a significant development in the U.S. market, stating, "The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business."

Looking Ahead

With a strong start to the fiscal year and a clear focus on innovation and market expansion, Sun Pharmaceutical Industries Limited appears well-positioned for continued growth. The company's balanced approach to maintaining its strong U.S. presence while focusing on global market opportunities demonstrates a strategic vision for sustainable long-term success in the pharmaceutical industry.